Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vedanta Biosciences
Biotech
Vedanta's live bacteria cocktail fails phase 2 colitis trial
Vedanta is reorienting resources toward lead candidate VE303, which is chasing the tail of Seres’ Vowst in treating recurrent C. diff infections.
Darren Incorvaia
Aug 13, 2025 1:48pm
Chasing Seres, Vedanta bags $107M to run phase 3 C. diff trial
Apr 25, 2023 9:40am
Vedanta CEO blames 'challenging environment' for 20% layoffs
Aug 11, 2022 4:58am
Founder-led biotech makes space for ideas—and diverse leaders
Nov 23, 2021 7:00am
Vedanta raises $68M, reveals setback to Bristol Myers alliance
Jul 21, 2021 8:11am
Pfizer invests $120M in 4 biotechs through new growth fund
Jan 12, 2021 8:55am
